Wed, May 14, 11:21 AM (40 days ago)
### Summary of Scholar Rock Holding Corporation's Q1 2025 Financial Health and Performance **Ticker:** SRRK **Quarterly Financial Health:** - **Revenue:** $0 - **Net Loss:** $74.7 million - **Cash Flow:** Net cash used in operating activities was $78.7 million, primarily due to net loss and changes in assets and liabilities, partially offset by non-cash adjustments. - **Cash Position:** As of March 31, 2025, the company had $364.4 million in cash, cash equivalents, and marketable securities. **Performance Metrics:** - **Gross Margin:** Not applicable (no revenue) - **Operating Margin:** Not applicable (no revenue) - **Net Margin:** Not applicable (no revenue) **Earnings Changes:** - **Year-over-Year Change in Net Loss:** Increased by $17.87 million (31.4%) **Quarterly Performance Discussion:** - **Operating Expenses:** Increased by $18.67 million (32.0%) due to higher research and development and general and administrative expenses. - **Research and Development:** Increased by $5.58 million (13.0%) due to higher drug supply manufacturing and preclinical costs. - **General and Administrative:** Increased by $13.1 million (85.4%) due to higher employee-related costs and professional service fees. **Trends:** - **Operating Expenses:** Continued increase in R&D and G&A expenses. - **Cash Position:** Decrease in cash position due to operating activities and higher expenses. **Uncertainties:** - **Regulatory Approval:** Uncertainty surrounding the approval of apitegromab and other product candidates. - **Funding:** Need for additional capital to fund operations and potential commercialization. - **Market Conditions:** Economic uncertainties and potential impacts on supply chains and operations. **Future Operations Impact:** - **Commercialization:** Potential launch of apitegromab in Q4 2025 if approved. - **Clinical Trials:** Continued investment in clinical trials for apitegromab, SRK-181, and SRK-439. - **Funding:** Need for additional capital to support ongoing and future operations. **Note:** All amounts are in thousands ($000s).